15 completed, 2 active not recruiting, 2 recruiting, 2 withdrawn. 21 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 21 | Completed 15, Active not recruiting 2, Recruiting 2, Withdrawn 2 |
| Phase 2 | 3 | Completed 3 |
Follow Kidney Disease: new trials by email Literature Review of Kidney Disease trials Research Report on Kidney Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of GSK4771261 in Healthy Participants Aged 25 to 55 Years of Age Inclusive GSK4771261, Placebo - Kidney Disease | Phase 1 | Recruiting | GlaxoSmithKline | 30 | 2026-05-18 | 2026-10-05 |
| Adia Med of Winter Park LLC Chronic Kidney Disease Research Study Umbilical Cord Blood-Derived Stem Cells and Exosomes, Glutathione IV, Glutathione Spray - Chronic Kidney Disease, Kidney Disease | Phase 1 | Recruiting | Adia Med of Winter Park LLC | 100 | 2026-05-18 | 2026-06-17 |
| A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function LY3841136 - Kidney Disease, Renal Insufficiency Chronic | Phase 1 | Active not recruiting | Eli Lilly and Company | 28 | 2026-02-24 | 2026-08-19 |
| A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease GSK4771261, Placebo matching GSK4771261 - Kidney Disease | Phase 1 | Active not recruiting | GlaxoSmithKline | 86 | 2024-12-11 | 2026-07-30 |
| A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy Mezagitamab - Kidney Disease, Glomerulonephritis | Phase 1 | Completed | Takeda | 17 | 2022-08-16 | 2026-06-01 |
| Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects Nitazoxanide - Renal Impairment, Renal Disease | Phase 1 | Completed | Genfit | 77 | 2022-04-25 | 2022-10-28 |
| A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases N-acetyl D-mannosamine - Kidney Disease | Phase 1 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 10 | 2016-07-07 | 2023-02-24 |
| A Study to Evaluate the Pharmacokinetics Of Sativex® in Subjects With Severe Renal Impairment or End Stage Renal Disease, Compared to Matched Subjects With Normal Renal Function. Sativex - Renal Insufficiency, Kidney Disease | Phase 1 | Withdrawn | GW Pharmaceuticals Ltd | 2016-01-01 | 2016-08-11 | |
| Donor-Alloantigen-Reactive Regulatory T Cell (darTreg) Therapy in Renal Transplantation (The ONE Study ) darTreg infusion - Kidney Disease | Phase 1 | Completed | University of California, San Francisco | 6 | 2015-04-01 | 2018-10-15 |
| PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers IDN-6556 - Renal Impairment, Renal Insufficiency | Phase 1 | Completed | Conatus Pharmaceuticals Inc. | 16 | 2014-01-01 | 2016-01-28 |
| Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting PINTA 745, Placebo - End Stage Renal Disease, Kidney Disease | Phase 1 / Phase 2 | Completed | Pinta Biotherapeutics | 51 | 2014-01-01 | 2018-04-11 |
| A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function AMG 386 + Paclitaxel, AMG 386 - Advanced Solid Tumors, Kidney Disease | Phase 1 | Completed | Amgen | 35 | 2011-09-19 | 2017-11-06 |
| Study to Evaluate TRV120027 on Renal Pharmacodynamics in Patients With Heart Failure and Renal Dysfunction TRV120027, Normal Saline - Heart Failure, Kidney Disease | Phase 1 | Completed | Trevena Inc. | 17 | 2011-08-01 | 2012-08-27 |
| Pharmacokinetic Study in Patients With Chronic Kidney Disease and Healthy Volunteers Propranolol, Losartan, Eprosartan - Kidney Disease | Phase 1 | Completed | University of California, San Francisco | 24 | 2010-03-01 | 2013-05-30 |
| Single Dose Safety Study for Compound to Treat Anemia in Patients With Renal Impairment GSK1278863A, Placebo - Kidney Disease | Phase 1 | Completed | GlaxoSmithKline | 12 | 2009-08-12 | 2017-07-27 |
| Repeat Dose Safety Study for Compound to Treat Anemia 1278863, Placebo - Kidney Disease | Phase 1 | Completed | GlaxoSmithKline | 24 | 2009-03-13 | 2017-06-22 |
| Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients Alemtuzumab, Mycophenolate mofetil, Sirolimus - Kidney Transplantation, Kidney Disease | Phase 1 / Phase 2 | Completed | University of Miami | 9 | 2004-09-01 | 2012-10-02 |
| Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults Alemtuzumab, Sirolimus, Tacrolimus - Kidney Transplantation, Kidney Disease | Phase 1 / Phase 2 | Completed | University of Wisconsin, Madison | 10 | 2003-11-01 | 2018-06-29 |
| MRI to Detect Embolism Following Angiography and Angioplasty-Stenting of the Renal Artery MRI - Renal Artery Obstruction, Kidney Disease | Phase 1 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 60 | 2001-12-01 | 2008-03-04 |
| Oxaliplatin in Cancer Patients With Impaired Kidney Function Oxaliplatin - Kidney Disease, Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 60 | 1999-09-01 | 2008-03-04 |
Showing 20 of 21. Sign in to see all of them.
Kidney Diseases (21) · Renal Insufficiency (8) · Kidney Failure, Chronic (3) · Renal Insufficiency, Chronic (2) · Acquired Immunodeficiency Syndrome (1) · Atherosclerosis (1) · Bronchiolitis Obliterans Syndrome (1) · Embolism, Cholesterol (1) · Glomerulonephritis (1) · HIV Infections (1) · Heart Failure (1) · Hypertension, Renovascular (1) · Kidney Neoplasms (1) · Marijuana Abuse (1) · Neoplasm Metastasis (1)
Female Urogenital Diseases (21) · Female Urogenital Diseases and Pregnancy Complications (21) · Male Urogenital Diseases (21) · Urogenital Diseases (21) · Urologic Diseases (21) · Pathological Conditions, Signs and Symptoms (6) · Pathologic Processes (5) · Chronic Disease (4) · Disease Attributes (4) · Cardiovascular Diseases (2) · Immune System Diseases (2) · Renal Insufficiency (2) · Renal Insufficiency, Chronic (2) · Abnormalities, Multiple (1) · Arterial Occlusive Diseases (1)
Alemtuzumab (2) · Kidney Transplantation (2) · Sirolimus (2) · Tacrolimus (2) · 3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid (1) · Acetaminophen (1) · Acyclovir (1) · Clotrimazole (1) · Diphenhydramine (1) · Hydrochlorothiazide (1) · Losartan (1) · Methylprednisolone (1) · Mycophenolic Acid (1) · N-acetylmannosamine (1) · Nystatin (1)
GlaxoSmithKline (4) · University of California, San Francisco (2) · Adia Med of Winter Park LLC (1) · Amgen (1) · Conatus Pharmaceuticals Inc. (1) · Eli Lilly and Company (1) · GW Pharmaceuticals Ltd (1) · Genfit (1) · National Cancer Institute (NCI) (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Pinta Biotherapeutics (1) · Takeda (1) · Trevena Inc. (1)
United States (17) · Australia (2) · Netherlands (2) · Spain (2) · United Kingdom (2) · Belgium (1) · Canada (1) · China (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Japan (1) · New Zealand (1) · Singapore (1)
A. D'jamali, MD, MS (1) · Carol Addy, MD (1) · Christopher Haqq, MD, PhD (1) · Dave Hagerty, MD (1) · George W. Burke, III, MD (1) · Jeffrey B Kopp, M.D. (1) · Leslie Z Benet, PhD (1) · Lynda Frassetto, MD (1) · Richard Edwards, DO (1) · Sang-Mo Kang, M.D. (1) · Tartaglione TA (1)
PMID 13278189, PMID 23903014, PMID 32446407, PMID 40444214, PMID 40465397, PMID 41630898
2014 (1), 2025 (1)